Adc Therapeutics SA
NYSE:ADCT 4:00:00 PM EDT
| Market Cap (Intraday) | 392.85M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $4.65 |
| 50-Day MA | $4.59 |
| 200-Day MA | $2.15 |
Adc Therapeutics SA Stock, NYSE:ADCT
BiopÃ?Â?le, Route de la Corniche 3B, Epalinges, Vaud 1066
Switzerland
Phone: +41.212.653.02.00
Number of Employees: 162
Description
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.